Exceptional GMP flexibilities for medicines imported from third countries during the coronavirus (COVID-19) outbreak

This temporary guidance lists flexible approaches supported by the MHRA, including not carrying out product re-testing on importation if the batch has been fully tested in a Pharmaceutical Inspection Co-operation Scheme (PIC/S) participating country.

Medicines and Healthcare products Regulatory Agency